BioMedNewsBreaks Archive - Page 176 of 215

MondayFeb 22, 2021 10:46 am

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by Encode Ideas L.P., a health care focused research firm. The full research publication is available at https://ibn.fm/NqQs7. The report reads, “Processa’s pipeline is constructed of development-stage assets that have substantial legacy human data, where the company believes a new approach (dosing, indication, trial design, etc.) can unlock latent value. Processa’s management (David Young, Questcor) and board (Khalid Islam, Gentium and Fennec) have a history of successful drug reclamation…

MondayFeb 22, 2021 10:11 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Expedited Formation of Team to Launch Test System, Also Comments on Lawsuit Against German Subsidiary

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) announced that it has accelerated the creation of a commercial team formed to launch its point-of-care COVID-19 RT-PCR (“RT-PCR”) test system, called the COVID ID Lab. The lab was developed by XPhyto's exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"). It is anticipated that 3a will receive ISO 13485 medical device manufacturer approval by the end of February; European regulatory approval should be received by early March. The announcement noted that the market launch team consists of highly skilled clinical and pharmaceutical executives and service providers with the expertise and background to rapidly…

FridayFeb 19, 2021 2:12 pm

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Set to Benefit from Push Towards Biopesticides

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, looks set to benefit amid new demands and regulatory standards. “The change in market demanding residue-free and organic food combined with the ever-more stringent regulatory standards in the international agricultural food supply chain is pressuring farmers to adopt a sustainable method of farming using biopesticides,” reads an article on the recent developments. The preference for biopesticides is because they have “favorable” properties. “They do not leave residues in the products, and they do not harm natural pests’ enemies or…

FridayFeb 19, 2021 1:13 pm

BioMedNewsBreaks – PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) Publishes New Video for Plant-Based Investors

PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) has released a new video that highlights the company’s value proposition for investors. The piece discusses PlantX's platform that serves as the digital face of the plant-based community, offering comprehensive capabilities that provide a robust and user-friendly ecommerce experience. The platform offers a wide variety of plant-based grocery items, from products to suit all pantry needs, as well as vitamins, cosmetics and even pet food. PlantX also offers meal delivery with options created by well-known plant-based chefs throughout the world, as well as weekly, easy-to-follow recipes. The one-stop experience includes Plant…

FridayFeb 19, 2021 10:42 am

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $11.7M Private Placement

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced its entry into securities purchase agreements with certain institutional investors to raise approximately $11.7 million through the private placement of 2,564,000 shares of its common stock and accompanying warrants to purchase an aggregate of up to 2,564,000 shares of common stock at a combined purchase price of $4.55 per share and accompanying warrant. The warrants will be immediately exercisable at an exercise price of $5.00 per share and will expire five years…

FridayFeb 19, 2021 10:03 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) CEO Slated to Host Investor Meetings at Global Healthcare Conference

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has announced that CEO Erez Raphael will be participating in the upcoming SVB Leerink Global Healthcare Conference. The 10th annual SVB Leerink Healthcare Conference will be held Feb. 24–26, 2021. Raphael will participate in the premiere event and is also scheduled to host investor meetings during the three-day virtual gathering. DarioHealth is recognized for providing one of the highest-rated diabetes and hypertension solutions available today with a team of experts that have impressive experience in the life sciences, behavioral science and software technology sectors. The company is covering new…

ThursdayFeb 18, 2021 2:47 pm

BioMedNewsBreaks – Lincoln Health Network’s Upcoming Conference to Showcase Latest Innovations, Cover Every Facet of Clinical Doc Management

Lincoln Health Network, a renowned conference production company dedicated to shining a spotlight on the latest technologies and trends within the pharmaceutical, medical devices and biotech fields, today announced its plans to host the upcoming Clinical Document World conference. The event is set to take place in an entirely digital format on Feb. 24-26, 2021. The summit is designed to operate as a one-stop learning experience for life sciences professionals seeking to improve upon their clinical documentation process and will provide attendees with three days of sessions featuring faculty experienced in clinical documentation, trial master files, inspection readiness, risk management…

ThursdayFeb 18, 2021 12:53 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Key Milestone, Progress Toward Collaborative Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (8SV1.F) (“WPD”), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that WPD received a positive opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland for its planned upcoming Berubicin clinical trial in adults with Glioblastoma Multiforme (“GBM”) under the WPD-201 Clinical Trial Protocol. CNS Pharmaceuticals has received study level approval from the Central IRB for the CNS-201 Clinical Trial Protocol. Berubicin is the company’s novel anthracycline candidate for the treatment of a number…

ThursdayFeb 18, 2021 11:58 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $17.6M Private Placement

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into securities purchase agreements with certain institutional and accredited investors to raise approximately $17.6 million through the issuance of an aggregate of 9,043,766 shares of its common stock and warrants to purchase up to an aggregate of 4,521,883 shares of common stock, at a purchase price of $1.95 per share of common stock and associated warrant. The private placement is priced at-the-market under Nasdaq rules. Subject to the satisfaction of customary conditions, the closing of the private…

WednesdayFeb 17, 2021 12:16 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Signs Memorandum of Understanding with Ehave, Inc. (EHVVF) to Map Brain Response

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company with two FDA-cleared products, has entered into a memorandum of understanding (“MoU”) with Ehave, Inc. (OTC: EHVVF), a provider of digital therapeutics for the psychedelic and mental health sectors. The agreement calls for the two companies to work together to map brain response to psychedelics being administered as a treatment for chronic pain, depressions (both major and persistent), post-traumatic stress disorder, bipolar disorder, general anxiety, ADHD and schizophrenia. The two companies will also collaborate in the development of neural net algorithms for the mental-health sector. BRSF’s e-tattoo technology will be used to provide…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Expedited Formation of Team to Launch Test System, Also Comments on Lawsuit Against German Subsidiary

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Set to Benefit from Push Towards Biopesticides

BioMedNewsBreaks – PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) Publishes New Video for Plant-Based Investors

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $11.7M Private Placement

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) CEO Slated to Host Investor Meetings at Global Healthcare Conference

BioMedNewsBreaks – Lincoln Health Network’s Upcoming Conference to Showcase Latest Innovations, Cover Every Facet of Clinical Doc Management

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Key Milestone, Progress Toward Collaborative Clinical Trials

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $17.6M Private Placement

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Signs Memorandum of Understanding with Ehave, Inc. (EHVVF) to Map Brain Response

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search